Your session is about to expire
← Back to Search
Diagnostic Imaging with Copper Cu 64 PSMA I&T for Prostate Adenocarcinoma (Solar-Stage Trial)
Solar-Stage Trial Summary
This trial will test a new imaging technique using copper Cu 64 PSMA I&T injection in patients with newly diagnosed aggressive prostate cancer to see if it can help doctors better visualize the extent of the cancer
Solar-Stage Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSolar-Stage Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 711 Patients • NCT02175030Solar-Stage Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many locations is this trial currently being conducted?
"Nine clinical sites, such as Tower Urology in Los Angeles, VA Greater Los Angeles Healthcare System in Newport Beach, and Hoag Memorial Hospital Presbyterian in Tampa, are currently enrolling participants."
What is the current number of participants being enrolled in this research project?
"To conduct the research successfully, a total of 323 eligible individuals are required. The sponsor, Curium US LLC, will oversee the trial at various locations such as Tower Urology in Los Angeles, California and VA Greater Los Angeles Healthcare System in Newport Beach, Florida."
What are the risks associated with Diagnostic Imaging using Copper Cu 64 PSMA I&T for individuals?
"Power's evaluation of the safety level for Diagnostic Imaging using Copper Cu 64 PSMA I&T is rated as a 3, reflecting the extensive data on both efficacy and safety gathered through Phase 3 investigations."
Are there ongoing efforts to actively enroll participants for this clinical trial?
"According to the details available on clinicaltrials.gov, patient enrollment is currently ongoing for this investigation. The trial was first listed on 4/1/2024 and last revised on 4/23/2024."
Share this study with friends
Copy Link
Messenger